Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Not yet recruiting · NCT07703436 · Registry updated 2026-09-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, epithelial neoplasm, glioma, neoplasm, neuroepithelial neoplasm, oligodendroglioma, primitive neuroectodermal tumor | Not yet recruiting | Phase 2 | 2026-09-22 | NCT07703436 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Nuvation Bio Inc. | 11 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cleveland Clinic | Cleveland | United States | 21 |
| Columbia University Medical center | New York | United States | 224 |
| Indiana University | Indianapolis | United States | 160 |
| NYU Langone Health | New York | United States | 403 |
| Rutgers Cancer Institute | New Brunswick | United States | 41 |
| University of California, Los Angeles | Los Angeles | United States | 142 |
| University of California, San Francisco | San Francisco | United States | 294 |
| University of Miami Health | Miami | United States | 3 |
| Yale University | New Haven | United States | 76 |